IQVIA LTD.
Formerly known as Quintiles, the company operates as a UK subsidiary of the US-listed IQVIA Holdings Inc, providing clinical trial management, healthcare data analytics, and contract research services to the life sciences sector.
Get an alert when IQVIA LTD. files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£90M
+304.2% vs 2023
Net assets
£4B
+6.5% vs 2023
Employees
3,643
+0.8% vs 2023
Profit before tax
£344M
-40.9% vs 2023
Net assets
2-year trend · vs Technology median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £2,752,678,000 | £3,004,120,000 | +9.1% | |
| Operating profit | £255,841,000 | £292,556,000 | +14.4% | |
| Profit before tax | £582,166,000 | £344,243,000 | -40.9% | |
| Net profit | £539,790,000 | £307,743,000 | -43% | |
| Cash | £22,203,000 | £89,751,000 | +304.2% | |
| Total assets less current liabilities | £3,713,068,000 | — | — | |
| Net assets | £3,713,068,000 | £3,954,478,000 | +6.5% | |
| Equity | £3,713,068,000 | £3,954,478,000 | +6.5% | |
| Average employees | 3,615 | 3,643 | +0.8% | |
| Wages | £277,694,000 | £288,156,000 | +3.8% | |
| Directors' remuneration | £4,491,000 | £5,311,000 | +18.3% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 9.3% | 9.7% | |
| Net margin | 19.6% | 10.2% | |
| Return on capital employed | 6.9% | — | |
| Gearing (liabilities / total assets) | 19.6% | 12.1% | |
| Current ratio | 0.88x | 0.80x | |
| Interest cover | 6.29x | 3.58x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- IQVIA LTD. 2017-11-03 → present
- QUINTILES LIMITED 2000-12-29 → 2017-11-03
- QUINTILES SCOTLAND LIMITED 1995-02-15 → 2000-12-29
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“We have concluded that the use of the going concern basis of accounting in the preparation of the financial statements is appropriate. However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the company’s ability to continue as a going concern.”
Group structure
- IQVIA LTD. · parent
- Q Squared Solutions Holdings Limited 60%
- Clintec Luxembourg S.A. 100%
- Clinical Lab Minority Shareholder Limited 100%
- IQVIA RDS Austria GmbH 100%
- IQVIA RDS Pty. Limited 100%
Significant events
- “On 4 March 2024, the company acquired the entire issued share capital of Arc Bio Communications Limited for £18.50 million.”
- “On 2 May 2024, the company acquired the entire issued share capital of Ceuta Holdings Limited.”
- “On 27 June 2024 the company acquired the trade and assets of Healthcare Business Information Limited for £10.60 million.”
- “In addition, on 28 June 2024 the company acquired the trade and assets of LH Perspectives Limited for £34.33 million.”
- “During December 2024 the company reorganised its investment in the PharmaReview group which resulted in: £47.90 million spent to acquire PharmaReview Limited; £56 million spent to acquire Pharmaspectra Group Ltd.”
- “On 13 May 2025, the company sold the entire issued share capital of Ceuta Holdings Limited, for £62.67m, to IQVIA IES European Holdings.”
- “On 11 June 2025, the company acquired the shares of Medicines Evaluation Unit Limited and CRO Solutions Limited for £122.8m.”
- “On 1 July 2025, the company acquired the trade of PharmaReview Limited for £47.91m and also the entire issued share capital of Apira Limited for £11.13m.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| JTC (UK) LIMITED | Corporate Secretary | 2023-06-21 | — | — |
| BERKSHIRE, James Grant | Director | 2020-02-07 | Jun 1973 | British |
| KOTCHIE, Natalia Alexandra | Director | 2020-10-08 | May 1985 | American |
| RANDALL, Kerry Louise | Director | 2023-11-28 | Jul 1980 | British |
| SHEPPARD, Timothy Peter | Director | 2020-02-07 | Jan 1971 | British |
| TURLAND, Kevin John | Director | 2014-02-28 | Mar 1969 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| WILSON, Michael Norman | Secretary | 1995-02-15 | 2014-02-28 |
| HALCO SECRETARIES LIMITED | Corporate Secretary | 2018-04-10 | 2023-06-21 |
| LONDON LAW SECRETARIAL LIMITED | Corporate Nominee Secretary | 1995-02-15 | 1995-02-15 |
| GILLINGS, Dennis Barry, Dr | Director | 1995-02-15 | 1999-12-23 |
| GOODACRE, John | Director | 1999-12-23 | 2015-12-17 |
| LATTIMORE, Barry Keith | Director | 2018-12-18 | 2020-05-29 |
| MACDONALD, Alasdair | Director | 2000-07-31 | 2018-12-31 |
| REYNDERS, Ludo, Dr | Director | 1995-02-15 | 2004-06-10 |
| WILSON, Michael Norman | Director | 1995-02-15 | 2014-02-28 |
| LONDON LAW SERVICES LIMITED | Corporate Nominee Director | 1995-02-15 | 1995-02-15 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Quintiles Holdings | Legal person | Shares 75–100% | 2016-04-06 | Ceased 2016-04-06 |
| Iqvia Rds Holdings | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 169 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-12-12 RESOLUTIONS Resolution
- 2023-04-27 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-08 | AA | accounts | Accounts with accounts type full | |
| 2025-07-09 | CH01 | officers | Change person director company with change date | |
| 2025-02-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-12-12 | RESOLUTIONS | resolution | Resolution | |
| 2024-12-09 | SH01 | capital | Capital allotment shares | |
| 2024-09-23 | AA | accounts | Accounts with accounts type full | |
| 2024-02-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-30 | AP01 | officers | Appoint person director company with name date | |
| 2023-11-06 | CH01 | officers | Change person director company with change date | |
| 2023-10-09 | AD02 | address | Change sail address company with old address new address | |
| 2023-10-06 | AP04 | officers | Appoint corporate secretary company with name date | |
| 2023-10-06 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-10-06 | AA | accounts | Accounts with accounts type full | |
| 2023-04-27 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2023-04-27 | RESOLUTIONS | resolution | Resolution | |
| 2023-04-27 | CAP-SS | insolvency | Legacy | |
| 2023-04-27 | SH20 | capital | Legacy | |
| 2023-04-17 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-02-28 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 1
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.